Malignant Melanoma, Telemedicine
Conditions
Keywords
Malignant Melanoma, Telemedicine
Brief summary
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
Interventions
None listed
Sponsors
Deutsche Krebshilfe e.V., Bonn (Germany)
University Hospital, Bonn
University Hospital Dresden
University Hospital Muenster
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board . Inclusion criteria for patients: * Minimum age 18 years * Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of: * Malignant melanoma from stage IIB * Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB. In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved. Inclusion criteria for external doctors: * has a medical license * has dermatological patients who are eligible to be presented in the vTB+
Exclusion criteria
Patients will be excluded from the study if they meet the following criteria: * Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy. * No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presentation of external patients in the video-tumorboard | Day 365 | Increase in the proportion of external patients in the video-tumorboard |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Increase in the proportion of external patients invited to a clinical study | Day 365 | Increase in the proportion of external patients in clinical studies |
| Adherence to tumorboard recommendations for external patients | Up to two weeks after inclusion | Proportion of implemented tumorboard recommendations for external patients |
| Offer of supportive therapies by the comprehensive cancer center | Up to two days after inclusion | Proportion of (external) patients who are offered at least one supportive therapy (e.g. psychooncology) within the video-tumorboard |
| Duration of the transmission of the tumorboard recommendations | Up to two weeks after inclusion | Duration of the transmission of the tumorboard recommendations |
| Time to integration into palliative care | Once per patient within two weeks after transmission of the tumorboard recommendation if applicable | Time between medical recommendation for palliative care and first contact with palliative care |
Countries
Germany
Contacts
Primary ContactPhilipp Lenz, MD
Backup ContactFriedegund Meier, MD
Outcome results
None listed